株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中国のベバシズマブ市場の分析

Investigation Report on China Bevacizumab Market ,2010-2019

発行 China Research and Intelligence 商品コード 296861
出版日 ページ情報 英文 20 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
中国のベバシズマブ市場の分析 Investigation Report on China Bevacizumab Market ,2010-2019
出版日: 2015年07月24日 ページ情報: 英文 20 Pages
概要

ベバシズマブは、中国市場に参入以降、急成長を示しています。年間売上高は、2013年には2億6,500万人民元に達し、2010年〜2014年のCAGRで126.67%の成長を遂げました。

当レポートでは、中国のベバシズマブ市場について調査分析し、市場規模、市場シェア、小売価格、主要メーカー、市場見通しなどについて、体系的な情報を提供しています。

第1章 ベバシズマブの関連概念

  • 適応
  • 世界市場の販売状況

第2章 中国のベバシズマブの市場プロファイル

  • 特許状況と承認情報
  • 主要メーカー
  • 市場規模

第3章 中国のベバシズマブの販売状況の分析

  • 売上高
  • 売上数量

第4章 中国のベバシズマブ主要メーカーの市場シェア分析

  • 市場シェア:売上高別
  • 市場シェア:売上数量別

第5章 中国のベバシズマブの剤形別の分析

  • 市場シェア (剤形別) :売上高別
  • 市場シェア (剤形別) :売上数量別

第6章 中国のベバシズマブの病院向け基準価格

第7章 中国のベバシズマブ市場の主要メーカー

第8章 中国のベバシズマブの市場見通し

  • 市場規模の予測
  • 競合情勢の予測

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 1507277

Colon cancer is a common gastrointestinal tumor whose incidence varies greatly in different countries. In developed countries, colon cancer is only second to lung cancer among malignant cancers. Its incidence decreases every year in the US and the EU but increases remarkably during the past four decades in Japan. According to the statistics published by the Ministry of Health of the People's Republic of China in 2011, 92-170 out of 1 million people suffer from colon cancer, sex ratio for which is 1.2:1. Although the incidence of colon cancer in China is higher than that in developed countries, it has decreased slightly in recent years.

Developed by Roche under the trade name of Avastin, bevacizumab injection is the first angiogenesis inhibitor in the world. In Feb.26, 2010, it was approved by CFDA to treat metastatic colorectal cancer. Currently, bevacizumab injections available in China all come from Roche and its subsidiary Genectech. In Jul. 2013, Kanion Pharmaceutical's Establishment of Evaluation System of Traditional Chinese Medicine's Efficacy in Treating Gastrointestinal Inflammatory Disease as well as Jiangsu Hengrui Medicine Co., Ltd's Introduction of Monoclonal Antibody Technology and Development of Bevacizumab have been designated by the Ministry of Science and Technology of the People's Republic of China as Key International S&T Cooperation Projects. In Dec. 2013, phase I clinical trial of the generic drug of bevacizumab co-developed by Huahai Pharmaceutical and Oncobiologics was approved to be conducted in the EU.

Bevacizumab injection develops fast after entering China, sales value reaching CNY 265 million in 2013 despite a slight decline in 2014 and CAGR during the period of 2010-2014 reaching 126.67%. With improvements in living standards and lifestyle changes, obesity rate in China goes up gradually, which increases the risk of colorectal cancer. Hence the vast demand for bevacizumab injection in China. Currently, the market is monopolized by Shanghai Roche Pharmaceutical Co., Ltd that brought in a sales value of CNY 264 million in 2014. As some local enterprises are trying to make generic drugs of bevacizumab injection, the monopoly of Roche is expected to be broken by local products in the next few years.

Readers can get at least the following information from this report:

  • market size of bevacizumab in China
  • competitive landscape of bevacizumab in Chinese market
  • price of bevacizumab made by different enterprises in China
  • market outlook of bevacizumab in China

The author suggests the following groups of people purchase this report:

  • manufacturers of monoclonal antibody
  • manufacturers of anti-tumor drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Bevacizumab

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Bevacizumab in China

  • 2.1. Patent Status and Approval Information of Bevacizumab in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Bevacizumab in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Bevacizumab in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Bevacizumab in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Bevacizumab in Chinese Hospitals in 2014

7. Major Manufacturers of Bevacizumab in Chinese Market, 2010-2014

8. Market Outlook of Bevacizumab in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Approval Information of Bevacizumab in China
  • Chart Sales Status of Bevacizumab in China
  • Chart Sales Value of Bevacizumab in China, 2010-2014
  • Chart Sales Value of Bevacizumab in Some Regions in China, 2010-2014
  • Chart Sales Volume of Bevacizumab in China, 2010-2014
  • Chart Sales Volume of Bevacizumab in Some Regions in China, 2010-2014
  • Chart Sales Value and Market Share of Bevacizumab Made by Shanghai Roche Pharmaceutical Co., Ltd in China, 2010-2014
  • Chart Sales Value and Market Share of Bevacizumab Made by Genentech in China, 2010-2014
  • Chart Sales Volume and Market Share of Bevacizumab Made by Shanghai Roche Pharmaceutical Co., Ltd in China, 2010-2014
  • Chart Sales Volume and Market Share of Bevacizumab Made by Genectech in China, 2010-2014
  • Chart Sales Value and Market Share of Bevacizumab Injection in China, 2010-2014
  • Chart Sales Volume and Market Share of Bevacizumab Injection in China, 2010-2014
  • Chart Price of Bevacizumab Made by Shanghai Roche Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top